×
Hero Background

MEA Colorectal Cancer Companies

ID: MRFR/MED/1911-HCR
80 Pages
Kinjoll Dey
October 2025

Colorectal cancer treatment in the Middle East and Africa is primarily provided by a combination of public and private healthcare institutions. Several pharmaceutical and biotechnology companies play a crucial role in developing and providing treatment options

Share:
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Top Industry Leaders in the MEA Colorectal Cancer Market

Middle East and Africa Colorectal Cancer Key Companies

Latest Middle East and Africa Colorectal Cancer Companies Update



AstraZeneca Secured regulatory approval for Imfinzi (durvalumab) for the treatment of stage III colorectal cancer in several MEA countries. This expands access to a key checkpoint inhibitor therapy.


Roche Launched Elepsys (bevacizumab) in combination with chemotherapy for the treatment of metastatic colorectal cancer in several MEA markets. This provides another targeted therapy option for advanced disease


Johnson & Johnson Partnered with local healthcare institutions in Egypt and South Africa to implement training programs for colorectal cancer screening and diagnosis.


Merck KGaA Collaborating with regional oncology centers to establish clinical research networks for the development and evaluation of new colorectal cancer treatments in the MEA region.


List of Middle East and Africa Colorectal Cancer Key Companies in the Market



  • Hoffmann-La Roche Ltd (Switzerland)

  • Amgen Inc. (US)

  • Novartis AG(Switzerland)

  • Abbott (US)

  • Beckman Coulter Inc. (US)

  • Debiopharm Group (Switzerland)

  • AbbVie Inc. (US)

  • Bayer AG (Germany)